GlassScriptPhysician profile
Michele R Compton
NPI 1629103536
$4,392.98
in general payments reported to CMS, 2019-2025
23 companies · $991 in 2025
The $991 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $886 · 2023: $1,380 · 2024: $1,136 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,173 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.20 |
| Education | $333.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $963.49 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $714.18 | 2022-2025 | Ilumya |
| Lilly USA, LLC | $494.01 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $386.92 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $318.77 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $264.73 | 2022-2024 | Vtama |
| Incyte Corporation | $185.79 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $150.81 | 2022-2023 | Adbry |
| Ucb, INC. | $126.55 | 2024-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $123.12 | 2022 | |
| Pfizer INC. | $106.55 | 2023-2025 | |
| Genzyme Corporation | $106.09 | 2023-2025 | |
| Amgen INC. | $100.19 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $61.27 | 2023-2025 | Nemluvio, Epsolay |
| Organon LLC | $60.78 | 2025 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $56.92 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $38.16 | 2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $34.17 | 2023 | |
| Organogenesis INC. | $24.14 | 2025 | Affinity |
| Almirall LLC | $22.72 | 2024 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.02 | 2024 | Siliq |
| Botanix Sb INC | $18.83 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $15.77 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.